Nivolumab and Pembrolizumab for Non–Small Cell Lung Cancer

DOI PDF 3 Citations
  • Daniel Morgensztern
    1Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.
  • Roy S. Herbst
    2Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, Connecticut.

Description

<jats:title>Abstract</jats:title> <jats:p>The outcomes for patients with previously treated advanced stage non–small lung cancer (NSCLC) are very poor, with a modest benefit from chemotherapy over best supportive care. Immunotherapy offers a novel approach for the treatment of these patients, with two anti-programmed death 1 (PD-1) checkpoint inhibitors, nivolumab and pembrolizumab, recently approved by the FDA based on large randomized clinical trials showing increased overall survival compared with standard second-line docetaxel. Although only a subset of patients benefit from these drugs, the treatment is usually well tolerated and the responses are often durable, with an unprecedented number of survivors 3 years after starting the therapy. The next steps should be the identification of reliable predictors for benefit from immunotherapy with checkpoint inhibitors and the pursuit of well-designed combination therapies. In this article, we review the rationale for the use of checkpoint inhibitors in NSCLC, the data from phase I and randomized clinical trials, and future directions. Clin Cancer Res; 22(15); 3713–7. ©2016 AACR.</jats:p>

Journal

  • Clinical Cancer Research

    Clinical Cancer Research 22 (15), 3713-3717, 2016-07-31

    American Association for Cancer Research (AACR)

Citations (3)*help

See more

Details 詳細情報について

Report a problem

Back to top